Pacific Biosciences Of California (PACB) Assets Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.99% |
| Dec 31, 2025 | 13.63% |
| Sep 30, 2025 | 21.74% |
| Jun 30, 2025 | 31.04% |
| Mar 31, 2025 | 29.67% |
| Dec 31, 2024 | 53.48% |
| Sep 30, 2024 | 58.25% |
| Jun 30, 2024 | 54.66% |
| Mar 31, 2024 | 55.18% |
| Dec 31, 2023 | 59.29% |
| Sep 30, 2023 | 59.67% |
| Jun 30, 2023 | 68.25% |
| Mar 31, 2023 | 64.60% |
| Dec 31, 2022 | 65.09% |
| Sep 30, 2022 | 63.04% |
| Jun 30, 2022 | 60.18% |
| Mar 31, 2022 | 70.22% |
| Dec 31, 2021 | 70.85% |
| Jun 30, 2021 | 50.50% |
| Mar 31, 2021 | 54.97% |
| Dec 31, 2020 | 25.86% |
| Sep 30, 2020 | 24.66% |
| Jun 30, 2020 | 17.16% |
| Mar 31, 2020 | 17.14% |
| Dec 31, 2019 | 3.53% |
| Sep 30, 2019 | 3.73% |
| Jun 30, 2019 | 5.87% |
| Mar 31, 2019 | 5.64% |
| Dec 31, 2018 | 4.57% |
| Sep 30, 2018 | 3.66% |
| Jun 30, 2018 | 0.41% |
| Dec 31, 2017 | 2.13% |
| Mar 31, 2017 | -7.00% |
| Dec 31, 2016 | -8.78% |
| Sep 30, 2016 | -8.74% |
| Jun 30, 2016 | -9.18% |
| Dec 31, 2015 | -15.58% |